MWN-105

N/A

Report date: 2026/04/21 20:00:18

Base Information

Drug NameMWN-105
Drug Alias NameMWN-105
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionGlucose-Dependent Insulinotropic Polypeptide Receptor agonistsGlucagon-like peptide 1 receptor agonistsFibroblast growth factor 21 agonists
TargetsGlucose-Dependent Insulinotropic Polypeptide ReceptorGlucagon-like peptide 1 receptorFibroblast growth factor 21
Therapy Area/IndicationsOverweightObesityHyperlipidemias +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesShanghai Minwei Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Minwei Biotechnology Co LtdSidera Bio Aps
Inactive CompaniesN/A
Active IndicationsOverweightObesityHyperlipidemias +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A